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Abstract. Purpose: to study the feasibility of using the new radiopharmaceutical based on the technetium-99m-labeled 
gamma-alumina for identification of sentinel lymph nodes (SLNs) in breast cancer patients. The study included two 
groups of breast cancer patients who underwent single photon emission computed tomography (SPECT) and 
intraoperaive gamma probe identification of sentinel lymph nodes (SLNs). To identify SLNs, the day before surgery 
Group I patients (n = 34) were injected with radioactive 99mTc-Al2O3, and Group II patients (n = 30) received 99mTc-
labeled phytate colloid. A total of 37 SLNs were detected in Group I patients. The number of identified SLNs per patient 
ranged from 1 to 2 (the average number of identified SLNs was 1.08). Axillary lymph nodes were the most common site 
of SLN localization. 18 hours after 99mTc-Al2O3 injection, the percentage of its accumulation in the SLN was 7–11% (of 
the counts in the injection site) by SPECT and 17–31% by gamma probe detection. In Group II SLNs were detected in 
27 patients. 18 hours after injection of the phytate colloid the percentage of its accumulation in the SLN was 1.5–2% out 
of the counts in the injection site by SPECT and 4–7% by gamma probe. The new radiopharmaceutical based on the 
99mTc-Al2O3 demonstrates high accumulation in SLNs without redistribution through the entire lymphatic basin. The 
sensitivity and specificity of 99mTc-Al2O3 were 100% for both SPECT and intraoperative gamma probe identification. 
INTRODUCTION 
Development of the sentinel node concept started at the beginning of the 1990s with evaluation and comparison 
of the procedures that could be used to detect the sentinel node(s). 
If the SLN is free of metastatic disease, all other lymph nodes will also be free of disease [0, 0]. The use of 
colloid radiopharmaceuticals labeled with technetium-99m appeared to be effective and safe for scintigraphic and/or 
intraoperative gamma probe identification of SLN [0]. Sentinel node biopsy may be a reasonable alternative to avoid 
extensive axillar lymph node dissection in breast cancer patients with negative SLNs, thereby improving the quality 
of life of approximately 100 000 patients undergoing lymphodissection for treating breast cancer [0, 0–0]. The two 
most widely accepted clinical scenarios for SLN biopsy are melanoma and breast cancer. Most modern medical 
centers worldwide now offer SLN biopsy for these malignancies, yet debate continues regarding whether SLN 
biopsy should be routinely used in clinical practice [0, 0, 0, 0, 7]. 
The size of radioactive particles is the most important factor in determining the choice of radiopharmaceuticals. 
A.J. Schauer et al. [0] reported that a colloid with the particle size of less than 50 nm can be accumulated not only in 
the SLN but also in the non-SLNs. Particles of a greater size than 100 nm slowly migrate from the injection site. A 
colloid with the particle size of the order of 50–80 nm may be preferable for the SLN detection. Nanocolloids made 
to date are based on the compounds that form stable hydrosols, and organic substances of different structures are 
often chosen as starting materials for their production. Another type of such pharmaceuticals is represented by 
inorganic complexes with 99mTc-rhenium sulfide and antimony, the application of which are limited by their 
complex manufacturing process and high cost. Our studies showed that stable colloidal compounds can be obtained 
in a simpler way—by means of adsorption on the reduced 99mTc alumina gamma [8, 9]. The original premise for 
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the use of alumina as a “carrier” of 99mTc-label is its relatively low toxicity combined with good adsorption 
properties, availability and low cost. 
A specific feature of this compound is an organic coating of nanoparticles. During passage through the lymphatic 
system, nanoparticles lose their organic coating and accumulate in SLN without redistribution in the body. 
Breast cancer is the most common cancer in women worldwide. Approximately 30 000 new early stage breast 
cancer cases are diagnosed each year in Russia [0]. However, in patients with early stages of breast cancer, regional 
lymph node metastases are found in only 10–30% of cases. Extended lymph node dissection may increase the risk of 
postoperative complications [0]. 
The purpose of our study was to evaluate the feasibility of using the new radiopharmaceutical, based on 
technetium-99m-labeled gamma-alumina for the detection of sentinel lymph nodes in breast cancer patients. 
MATERIALS AND METHODS 
The study included 64 patients with histologically verified breast cancer (T1-2N0-1M0). For SLN visualization, 
all patients were divided into two groups. Group I consisted of 34 women, who received 4 peritumoral injections of 
radioactive 99mTc-Al2O3 at a total dose of 80 MBq (20 MBq per quadrant) the day before surgery. Group II 
comprised 30 women, who were injected with phytate colloid at a total dose of 80 MBq (4 peritumoral injections, 
20 MBq per injection) the day before surgery (Fig. 1). 
All patients underwent single photon emission computed tomography (SPECT) using the dual-head gamma 
camera (E.CAM 180, Siemens, energy 140 keV, window 15%) in 18 hours after the radiotracer injection. A total of 
16 projections were acquired (30 seconds per projection, matrix size 64?64). The scan images were analyzed using 
the ESoft software (Siemens, Germany). Three-dimensional images of the sagittal, transverse and coronal sections 
were obtained. To obtain quantitative values, the axial sections were used. The radiotracer accumulation in the SLN 
with respect to the injection site was evaluated using a quantitative criterion. 
For intraoperative detection of sentinel lymph nodes, the hand-held collimated Gamma Finder II® probe was 
used, which allowed the surgeon to precisely locate gamma radiation source and obtain accurate information about 
the distribution of the radionuclide in the patient’s tissues and organs. The registered gamma radiation level was 
displayed in numerical values. The lymph node with radioactivity of at least three times more than the background 
counts was defined as a sentinel lymph node. 
The sentinel lymph node was marked and separately sent for express cytological examination. The lymph node 
was sectioned transversely into 2 mm slices. Depending on the size of the node, 6–10 imprints were made from each 
slice by gently touching the cut surface of the node to a glass slide. Cytological specimens were stained for 15 s 
using the kit for rapid staining of blood smears (Leucodiff 200) and examined with a Zeiss Axio Scope (Germany). 
Each group of the patients was subdivided into the groups of 12 patients who underwent extended lympho-
dissection despite the results of histological examination. After lymphodissection, the removed lymph nodes were 
re-examined with gamma probe to detect SLNs missed during intraoperative examination. 
RESULTS AND DISCUSSION 
A total of 37 SLNs were identified in Group I patients. The number of identified SLNs per patient ranged from 1 
to 2 (the mean number of identified SLNs was 1.08). The most frequent SLN location was the axillary region 
(97.2%) (Fig. 2).  
Metastases in the excised SLNs were detected in 9 patients (26.6%), who subsequently underwent the 
conventional axillary lymph node dissection. Four patients (11.4%) had metastases not only in the SLN but also in 
lymph nodes of level II. The presence of SLN metastasis indicated lymphatic dissemination of tumor cells and the 
formation of clinically undetectable regional lymph node metastases. Sentinel lymph node was free from metastasis 
in 25 patients (73.5%). We did not observe the phenomenon of the so called “jumping” metastases in these patients. 
The 99mTc-Al2O3 uptake in the SLN in 18 hours after the injection was 7–11% (of the radioactivity in the 
injection site) by SPECT and 17–31% by intraoperative gamma probe detection. 
Thus, the sensitivity and specificity of 99mTc-Al2O3 for detecting SLNs in breast cancer patients were 100%. 
The intraoperative SLN detection was performed through a small skin incision. Sparing surgical procedures can 
significantly reduce overall surgery trauma and recovery time (Fig. 3). 
In Group II, 28 SLNs were identified in 27 patients. The number of SLNs detected per patient ranged from 1 to 2 
(the mean number of detected SLNs was 1.04). All detected SLNs were located in the axillary region. 
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FIGURE 1. Injection of the radiopharmaceutical in breast 
cancer 
FIGURE 2. SPECT SLN detection in breast cancer patients 
 
Metastases in the excised SLNs were detected in 8 patients (29.6%), who subsequently underwent the 
conventional axillary lymph node dissection. In 6 patients (22. 2%), the removed SLN and lymph nodes of the level 
II had a positive histology. In 21 patients (77.7%), the SLN was negative, with no clinical evidence of lymph node 
metastasis during the follow-up. In this group of patients, there was also no phenomenon of so called “jumping” 
metastases. 
The percentage of phytate colloid accumulation in the SLN in 18 hours after injection was 1.5–2% by SPECT 
and 4–7% by intraoperative gamma probe detection. 
Thus, the use of phytate colloid for detecting SLNs in breast cancer patients demonstrated 90% sensitivity. 
Various techniques of SLN identification are widely discussed in the published literature. Currently, most 
investigators propose that the blue dye and isotope complement each other, and the detection of SLN is more 
successful using combined dye- isotope technique, with sensitivity and specificity approaching 100% [10, 11]. In 
our study, the use of 99mTc-Al2O3, a novel molecular imaging agent showed promising results in detecting SLNs 
with high sensitivity and specificity. 
For histological examination of the identified sentinel lymph nodes, we used the light optical microscopy with 
hematoxylin-eosin. A number of authors have published immunohistochemistry and flow cytophluorometry for the 
detection of micrometastases in lymph nodes, allowing a three-fold increase in the detection rate to be achieved [12].  
The wide use of the modern methods of histological express analysis will significantly improve the clinical 
significance of detecting the sentinel lymph nodes in breast cancer patients. Thus, the use of the new 
radiopharmaceutical allows the precise detection of SLNs to be achieved, thereby personalizing the extent of surgery 
in patients with primary operable breast and cervical cancers.  
CONCLUSION 
The novel radiopharmaceutical based on 99mTc-Al2O3 has high accumulation in sentinel lymph nodes, with no 
evidence of further redistribution along the lymphatic collector, thus significantly facilitating scintigraphic and 
intraoperative SLN identification. 
 
 
FIGURE 3. Intraoperative radio guided SLN detection with the use  
of the hand-held collimated gamma Finder II® in breast cancer patients 
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The sensitivity and specificity of using 99mTc-Al2O3 were 100% for both SPECT and intraoperative identification 
of sentinel lymph nodes. 
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